Evaluation of CD44 variant expression in oral, head and neck squamous cell carcinomas using a triple approach and its clinical significance

International Journal of Immunopathology and Pharmacology

Volumn 27, Issue 3, 2014, Pages 337-349

  Athanassiou Papaefthymiou, M ^a,b   Shkeir, O ^a   Kim, D ^b   Divi, V ^a   Matossian, M ^a   Owen, J H ^a   Czerwinski, M J ^a   Papagerakis, P ^b   McHugh, J ^a   Bradford, C R ^a   Carey, T E ^a   Wolf, G T ^a   Prince, M E ^a   Papagerakis, S ^a,c  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c University of Michigan   (United States)

Author keywords

Cancer stem cells; CD44 variants; Cell lines; Clinical outcome; Head and neck squamous carcinoma (HNSCC); Metastasis

Indexed keywords

CD44V ANTIGEN; CD44V6 ANTIGEN; CD44 PROTEIN, HUMAN; HERMES ANTIGEN; ISOPROTEIN;

ARTICLE; CANCER PATIENT; CANCER RECURRENCE; CANCER STAGING; CELL DIFFERENTIATION; CONTROLLED STUDY; FLOW CYTOMETRY; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; IMMUNOFLUORESCENCE; IMMUNOFLUORESCENCE MICROSCOPY; IN VIVO STUDY; KERATINOCYTE; LYMPH NODE METASTASIS; MOUTH SQUAMOUS CELL CARCINOMA; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR BIOPSY; TUMOR GROWTH; TUMOR LOCALIZATION; FLUORESCENT ANTIBODY TECHNIQUE; HEAD AND NECK TUMOR; IMMUNOLOGY; MOUTH TUMOR; PATHOLOGY; PHYSIOLOGY; SQUAMOUS CELL CARCINOMA; TUMOR CELL LINE;

ANTIGENS, CD44; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; FLUORESCENT ANTIBODY TECHNIQUE; HEAD AND NECK NEOPLASMS; HUMANS; MOUTH NEOPLASMS; PROTEIN ISOFORMS;

EID: 84908448807     PISSN: 03946320     EISSN: None     Source Type: Journal    
DOI: 10.1177/039463201402700304     Document Type: Article

References (31)

1. Prince ME, Sivanandan R, Kaczorowski A, et al. Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma. Proc Natl Acad Sci U S A 2007; 104:973- 78.
2. Shah JP, Johnson NW, Batsakis JG. Complications and their management. In: Singh B, Shah JP, editors. Oral cancer. 1st ed. London: Martin Dunitz, 2003; p. 367-72.
3. Davis SJ, Divi V, Owen JH, Bradford CR, Carey TE, Papagerakis S, Prince ME. Metastatic potential of cancer stem cells in head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 2010; 136:1260-66.
4. Krishnamurthy S, Dong Z, Vodopyanov D, Imai A, Helman JI, Prince ME, Wicha MS, Nor JE. Endothelial cell-initiated signaling promotes the survival and self-renewal of cancer stem cells. Cancer Res 2010; 70:9969-78.
5. Mannelli G, Gallo O. Cancer stem cells hypothesis and stem cells in head and neck cancers. Cancer Treat Rev 2012;38:515-39.
6. Hofmann M, Rudy W, Zoller M, Tolg C, Ponta H, Herrlich P, Gunthert U. CD44 splice variants confer metastatic behavior in rats: homologous sequences are expressed in human tumor cell lines. Cancer Res 1991;51:5292-97.
7. Arch R, Wirth K, Hofmann M, Ponta H, Matzku S, Herrlich P, Zoller M. Participation in normal immune responses of a metastasis-inducing splice variant of CD44. Science 1992; 257:682-85.
8. Gunthert U, Schwarzler C, Witting B, et al. Functional involvement of CD44, a family of cell adhesion molecules, in immune responses, tumour progression and haematopoiesis. Adv Exp Med Biol 1998; 451:43-49.
9. Levesque MC, Haynes BF. Activated T lymphocytes regulate hyaluronan binding to monocyte CD44 via production of IL-2 and IFN-gamma. J Immunol 2001; 166:188-96.
10. Rosemblatt M, Bono MR. Functional consequences of immune cell adhesion to endothelial cells. Curr PharmDes 2004; 10:109-20.
11. Marhaba R, Zoller M. CD44 in cancer progression: Adhesion, migration and growth regulation. J Mol Histol 2004; 35:211-31.
12. Barbour AP, Reeder JA, Walsh MD, Fawcett J, Antalis TM, Gotley DC. Expression of the CD44v2-10 isoform confers a metastatic phenotype: importance of the heparan sulfate attachment site CD44v3. Cancer Res 2003; 63:887-92.
13. Seiter S, Arch R, Reber S, Komitowski D, Ponta H, Herrlich P, Matzku S, Zoller M. Prevention of tumor metastasis formation by anti-variant CD44. J Exp Med 1993; 177:443-55.
14. Wittig B, Seiter S, Foger N, Schwarzler C, Gunthert U, Zoller M. Functional activity of murine CD44 variant isoforms in allergic and delayed type hypersensitivity. Immunol Lett 1997; 57:217-23.
15. Chu PG, Weiss LM. Keratin expression in human tissues and neoplasms. Histopathology 2002; 40:403-39.
16. Goldman JP, Blundell MP, Lopes L, Kinnon C, Di-Santo JP, Thrasher AJ. Enhanced human cell engraftment in mice deficient in RAG2 and the common cytokine receptor gamma chain. Br J Haematol 1998; 103:335-42.
17. Massengale M, Wagers AJ, Vogel H, Weissman IL. Hematopoietic cells maintain hematopoietic fates upon entering the brain. J Exp Med 2005; 201:1579-89.
18. Molofsky AV, He S, Bydon M, Morrison SJ, Pardal R. Bmi-1 promotes neural stem cell self-renewal and neural development but not mouse growth and survival by repressing the p16Ink4a and p19Arf senescence pathways. Genes Dev 2005; 19:1432-37.
19. Prochazka M, Gaskins HR, Shultz LD, Leiter EH. The non-obese diabetic SCID mouse: model for spontaneous thymomagenesis associated with immunodeficiency. Proc Natl Acad Sci U S A 1992; 89:3290-94.
20. Wagers AJ, Christensen JL, Weissman IL. Cell fate determination from stem cells. Gene Ther 2002; 9:606-12.
21. Franzmann EJ, Reatequi EP, Pedroso F, et al. Soluble CD44 is a potential marker for the early detection of head and neck cancer. Cancer Epidemiol Biomarkers Prev 2007; 16:1348-55.
22. Carey TE. Head and neck cancers. Human Cell Culture Vol II. JRW Masters and B. Palsson (Eds.) Kluwer Academic Publishers 1999; p:185-255.
23. Lin CJ, Grandis JR, Carey TE, Gollin SM, Whiteside TL, Koch WM, Ferris RL, Lai SY. Head and neck squamous cell carcinoma cell lines: established models and rationale for selection. Head Neck 2007; 29:163-88.
24. Izumi K, Tobita T, Feinberg SE. Isolation of human oral keratinocyte progenitor/stem cells. J Dent Res 2007; 86:341-46.
25. Fox SB, Fawcett J, Jackson DG, et al. Normal human tissues, in addition to some tumors, express multiple different CD44 isoforms. Cancer Res 1994; 54:4539- 46.
26. Ailles L, Prince M. Cancer stem cells in head and neck squamous cell carcinoma. Methods Mol Biol 2009; 568:175-93.
27. Joshua B, Kaplan MJ, Doweck I, Pai R, Weissman IL, Prince ME, Ailles LE. Frequency of cells expressing CD44, a head and neck cancer stem cell marker: correlation with tumor aggressiveness. Head Neck 2012;34:42-49.
28. Locke M, Heywood M, Fawell S, Mackenzie IC. Retention of intrinsic stem cell hierarchies in carcinoma-derived cell lines. Cancer Res 2005; 65:8944-50.
29. Nelson AD, Grandis JR. The role of CD44 in HNSCC. Cancer Biol Ther 2007; 6:125-26.
30. Papagerakis S, Pannone G. Epithelial-mesenchymal interactions in oral cancer metastasis. Oral Cancer K. U. Ogbureke, Tech 2012; p:373-88.
31. Misra S, Heldin P, Hascall VC, Karamanos NK, Skandalis SS, Markwald RR, Ghatak S. Hyaluronan- CD44 interactions as potential targets for cancer therapy. FEBS J 2011; 278:1429-43.